SCHEMBL20768626

SCHEMBL20768626

CCOC(=O)Cc1ccc([C@H](N)CO)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
CYP4Z1 Q86W10 1/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 2/20 0.39
LMNA P02545 3/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30039662 1.00 F2 (0.41) F2SMN1; SMN2CYP4Z1CYP4F2CYP4A11
SCHEMBL20768627 1.00 F2 (0.41) F2SMN1; SMN2CYP4Z1CYP4F2CYP4A11
SCHEMBL30039615 0.86 SMN1; SMN2 (0.39) F2SMN1; SMN2CYP4Z1CYP4F2CYP4A11
SCHEMBL19347284 0.86 SMN1; SMN2 (0.39) F2SMN1; SMN2CYP4Z1CYP4F2CYP4A11
SCHEMBL24208260 0.86 MAPT (0.42) F2SMN1; SMN2CYP4Z1CYP4F2CYP4A11
SCHEMBL20768579 0.82 KDM4E (0.42) NFKB1MAPTLMNAALDH1A1KDM4E
SCHEMBL13492093 0.82 CYP4Z1 (0.43) F2SMN1; SMN2CYP4Z1CYP4F2CYP4A11
SCHEMBL20768578 0.82 KDM4E (0.42) NFKB1MAPTLMNAALDH1A1KDM4E
SCHEMBL20768609 0.80 MAPT (0.48) F2SMN1; SMN2CYP4Z1CYP4F2CYP4A11
SCHEMBL19347429 0.80 MAPT (0.48) F2SMN1; SMN2CYP4Z1CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348386-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-11-02 US disclosed
US-20230348386-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-11-02 US disclosed
US-20230348386-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-11-02 US disclosed
EP-4234552-A2 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF Raze Therapeutics, Inc. (US) 2023-08-30 EP disclosed
EP-3426244-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2023-06-07 EP disclosed
EP-3426244-B1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS INC (US) 2023-06-07 EP disclosed
US-11535593-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-12-27 US disclosed
US-11535593-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-12-27 US disclosed
US-20220017464-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2022-01-20 US disclosed
US-20220017464-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2022-01-20 US disclosed
US-11014882-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-05-25 US disclosed
US-20190071400-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348386-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD F2 2771/4885SMN1; SMN2 4082/4885CYP4Z1 1839/4885
US-11535593-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD F2 2771/4885SMN1; SMN2 4082/4885CYP4Z1 1839/4885
US-11014882-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD F2 2771/4885SMN1; SMN2 4082/4885CYP4Z1 1839/4885
US-20190071400-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD F2 2771/4885SMN1; SMN2 4082/4885CYP4Z1 1839/4885
US-20220017464-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD F2 2771/4885SMN1; SMN2 4082/4885CYP4Z1 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.